









市场行情
/
股票
/
nasdaq-avdl
/

Avadel Pharmaceuticals PLC

AVDL

21.590USD

+0.010+0.05%

收盘 12/26, 16:00（美东）报价延迟15分钟

2.10B总市值

亏损市盈率 TTM



Avadel Pharmaceuticals PLC

21.590

+0.010+0.05%

概览公司财务分析

概览

公司

财务

分析

关于 Avadel Pharmaceuticals PLC 公司

Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.

Avadel Pharmaceuticals PLC简介



公司代码AVDL

公司名称Avadel Pharmaceuticals PLC

上市日期Feb 21, 2088

CEODivis (Gregory J)

员工数量188

证券类型Ordinary Share

年结日Feb 21

公司地址Block 10-1 Blanchardstown Corporate Park

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

国家Ireland

邮编15

电话35319015201

网址https://www.avadel.com/

公司代码AVDL

上市日期Feb 21, 2088

CEODivis (Gregory J)

Avadel Pharmaceuticals PLC公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

Mr. Peter J. Thornton

Independent Director

115.06K

Mr. Thomas S. Mchugh

Chief Financial Officer

100.40K

+14.35%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

Ms. Linda S. Palczuk

Independent Director

78.90K

Ms. Susan Rodriguez

Chief Operating Officer

Mr. Jerad Seurer

General Counsel and Corporate Secretary

Mr. Gregory J. (Greg) Divis, Jr.

Chief Executive Officer, Director

Dr. Naseem Amin, M.D.

Independent Director

Ms. Courtney Turiano

Investor Relations

名称

名称/职务

职务

持股

持股变动

Dr. Eric J. Ende, M.D.

Independent Director

219.90K

Mr. Peter J. Thornton

Independent Director

115.06K

Mr. Thomas S. Mchugh

Chief Financial Officer

100.40K

+14.35%

Dr. Mark Anthony Mccamish, M.D., Ph.D.

Independent Director

89.03K

Ms. Linda S. Palczuk

Independent Director

78.90K

Ms. Susan Rodriguez

Chief Operating Officer

收入明细

单位: USD更新时间: 3月3日周一

FY2020

FY2019

业务USD

名称

营收

占比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

地区USD

名称

营收

占比

United States

22.33M

100.00%

Ireland

0.00

0.00%

业务

地区

业务USD

名称

营收

占比

Vazculep

10.43M

46.70%

Akovaz

9.54M

42.74%

Bloxiverz

2.20M

9.85%

Other

159.00K

0.71%

股东统计

更新时间: 12月7日周日

持股股东

股东类型

持股股东

占比

Janus Henderson Investors

7.57%

BlackRock Institutional Trust Company, N.A.

6.26%

The Vanguard Group, Inc.

5.98%

Brandes Investment Partners, L.P.

5.55%

Two Seas Capital LP

5.47%

其他

69.17%

持股股东

占比

Janus Henderson Investors

7.57%

BlackRock Institutional Trust Company, N.A.

6.26%

The Vanguard Group, Inc.

5.98%

Brandes Investment Partners, L.P.

5.55%

Two Seas Capital LP

5.47%

其他

69.17%

股东类型

持股股东

占比

Investment Advisor

33.38%

Investment Advisor/Hedge Fund

31.72%

Hedge Fund

21.03%

Research Firm

4.62%

Venture Capital

3.46%

Individual Investor

1.06%

Pension Fund

0.46%

Bank and Trust

0.36%

Insurance Company

0.03%

其他

3.89%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

402

92.83M

119.15%

+3.65M

2025Q3

398

82.11M

112.88%

-1.35M

2025Q2

383

83.11M

109.34%

+2.70M

2025Q1

369

80.46M

107.15%

-23.08M

2024Q4

346

82.09M

100.78%

+4.35M

2024Q3

324

77.51M

94.69%

+670.00K

2024Q2

289

76.58M

80.85%

+4.27M

2024Q1

248

72.03M

68.66%

+6.05M

2023Q4

216

57.48M

70.10%

+1.83M

2023Q3

210

56.27M

69.82%

+253.21K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Janus Henderson Investors

11.13M

11.46%

-2.46M

-18.10%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.98M

6.16%

+1.29M

+27.56%

Jun 30, 2025

The Vanguard Group, Inc.

5.54M

5.71%

+1.66M

+42.73%

Jun 30, 2025

Brandes Investment Partners, L.P.

6.49M

6.68%

+820.47K

+14.48%

Jun 30, 2025

Two Seas Capital LP

6.16M

6.34%

+1.21M

+24.43%

Jun 30, 2025

Tontine Asset Management, LLC

5.18M

5.33%

-950.54K

-15.51%

Jun 30, 2025

Polar Capital LLP

4.00M

4.12%

-356.63K

-8.19%

Jun 30, 2025

Vivo Capital, LLC

2.68M

2.76%

Jun 30, 2025

State Street Investment Management (US)

2.07M

2.13%

+412.10K

+24.84%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Innovator IBD 50 Fund ETF

3.77%

Invesco Pharmaceuticals ETF

3.4%

iShares Neuroscience and Healthcare ETF

3.21%

ProShares Merger ETF

2.82%

State Street SPDR S&P Pharmaceuticals ETF

2.44%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

2.39%

AltShares Event-Driven ETF

1.21%

First Trust Small Cap Growth AlphaDEX Fund

1.02%

iShares U.S. Pharmaceuticals ETF

0.68%

Janus Henderson Small/Mid Cap Growth Alpha ETF

0.4%

Innovator IBD 50 Fund ETF

占比3.77%

Invesco Pharmaceuticals ETF

占比3.4%

iShares Neuroscience and Healthcare ETF

占比3.21%

ProShares Merger ETF

占比2.82%

State Street SPDR S&P Pharmaceuticals ETF

占比2.44%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比2.39%

AltShares Event-Driven ETF

占比1.21%

First Trust Small Cap Growth AlphaDEX Fund

占比1.02%

iShares U.S. Pharmaceuticals ETF

占比0.68%

Janus Henderson Small/Mid Cap Growth Alpha ETF

占比0.4%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Avadel Pharmaceuticals PLC的前五大股东是谁？



Avadel Pharmaceuticals PLC 的前五大股东如下：
Janus Henderson Investors持有股份：11.13M，占总股份比例：11.46%。
BlackRock Institutional Trust Company, N.A.持有股份：5.98M，占总股份比例：6.16%。
The Vanguard Group, Inc.持有股份：5.54M，占总股份比例：5.71%。
Brandes Investment Partners, L.P.持有股份：6.49M，占总股份比例：6.68%。
Two Seas Capital LP持有股份：6.16M，占总股份比例：6.34%。